A 70-year-old man with persistent atrial fibrillation (duration >48 hours) has a CHA2DS2-VASc score of 4. He is haemodynamically stable. Rate control is achieved with bisoprolol. Regarding anticoagulation: when can cardioversion be performed after initiating rivaroxaban?
- A Immediately after a single dose of rivaroxaban
- B After at least 3 weeks of therapeutic anticoagulation ✓
- C After TOE-guided exclusion of LA thrombus, regardless of anticoagulation duration
- D After 48 hours of rivaroxaban if AF duration is definitely <48 hours
Correct answer: B. After at least 3 weeks of therapeutic anticoagulation
Explanation
Per the 2020 ESC AF guidelines, cardioversion of AF with unknown or >48-hour duration requires at least 3 weeks of therapeutic anticoagulation beforehand (or TOE to exclude LA/LAA thrombus) to prevent thromboembolic events from atrial stunning post-cardioversion. DOACs are equivalent to warfarin for pre-cardioversion anticoagulation. Post-cardioversion anticoagulation must continue for at least 4 weeks regardless of CHA2DS2-VASc score (due to atrial stunning risk), and long-term based on stroke risk thereafter. The X-VeRT trial validated DOAC use in this setting.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.